How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings

Simply Wall St.17:32

Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnings per share from continuing operations ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681814213?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-11-07 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681814213","market":"nz","top_or_hot":-1,"title":"How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings","media":"Simply Wall St.","content":"<div>\n<p>Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnings per share from continuing operations ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/how-investors-are-reacting-to-amphastar-pharmaceuticals-amph-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/how-investors-are-reacting-to-amphastar-pharmaceuticals-amph-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnings per share from continuing operations ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/how-investors-are-reacting-to-amphastar-pharmaceuticals-amph-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/how-investors-are-reacting-to-amphastar-pharmaceuticals-amph-1","article_id":"2681814213","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/news/how-investors-are-reacting-to-amphastar-pharmaceuticals-amph-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681814213","pubTimestamp":1794043967,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","AMPH":"Amphastar Pharmaceuticals"},"translate_title":"投资者对 Amphastar Pharmaceuticals (AMPH) 强劲第三季度收益的反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"AMPH":1.5},"content_text":"Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year period. The nine month figures show sales of US$562.68 million and net income of US$74.53 million. This indicates that Amphastar Pharmaceuticals is converting its product mix and cost base into steadier profitability across the year, rather than concentrating performance in a single quarter. We will now review how this third quarter earnings performance from Amphastar Pharmaceuticals might influence the existing investment narrative.  Scan beyond Amphastar Pharmaceuticals and compare this earnings story with a curated 19 high quality undiscovered gems that are also quietly turning steady operations into growing profit potential. AdvertisementAmphastar Pharmaceuticals Investment Narrative Recap To own Amphastar Pharmaceuticals, you need to be comfortable with a story built on respiratory products, emergency injectables and a pipeline that aims to justify recent capacity and R&D spend. The Q3 2026 report, which shows higher sales and net income versus a year ago, supports the idea that current operations are holding up. The short term swing factor is how pricing pressure in glucagon, epinephrine and BAQSIMI rebates interacts with this product mix. The latest quarter does not remove that risk. It indicates that Amphastar Pharmaceuticals is currently offsetting some pressure through newer higher margin products and a broader base of inhalation and injectable therapies. The most relevant update is the Q3 2026 earnings report itself. Sales of US$207.61 million and net income of US$37.76 million for the quarter, along with higher basic and diluted EPS from continuing operations versus a year ago, provide a clearer read on execution while the firm scales newer drugs. For the nine months to September 30, 2026, Amphastar Pharmaceuticals reported sales of US$562.68 million and net income of US$74.53 million. That profile matters for the main catalyst. The key question is whether recent capital spending and the evolving mix in respiratory and injectable products can comfortably cover higher fixed costs and debt while the pipeline, including future biosimilars, moves closer to commercialization. Amphastar Pharmaceuticals' current analyst narrative points to revenue of US$839.3 million and earnings of US$112.6 million by 2029, based on assumed 4.8% yearly revenue growth and an earnings increase of about US$34.1 million from US$78.5 million today. Uncover why Amphastar Pharmaceuticals' fair value signals a 21% potential downside to its current price, which leaves little room for error. NasdaqGS:AMPH 1-Year Stock Price Chart Exploring Other Perspectives One alternative lens for Amphastar Pharmaceuticals focuses on the insulin aspart biosimilar as a future swing factor rather than current pricing pressure. The most optimistic analysts were penciling in revenue of about US$884.1 million and earnings of US$123.3 million by 2029. Those pre earnings call assumptions may shift once this new Q3 report is fully reflected. Explore 4 other Amphastar Pharmaceuticals fair value estimates, including one that suggests potential upside of as much as 185% from the current price. Reach Your Own Conclusion Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Amphastar Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Amphastar Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Amphastar Pharmaceuticals' overall financial health at a glance.  Looking for more Amphastar Pharmaceuticals style investment ideas? Once you have taken a view on Amphastar Pharmaceuticals, it can help to line that thesis up against other stocks with clear financial profiles using the Simply Wall St Screener.  If you prefer companies that the model views as potentially mispriced with quality fundamentals, compare Amphastar Pharmaceuticals with a 39 high quality undervalued stocks that meet those filters. For investors who care most about balance sheet strength and cleaner financial risk, scan a list of solid balance sheet and fundamentals (24 results) to see which businesses fit that profile. If stability and smaller drawdowns matter to your plan, broaden your watchlist with a 29 resilient stocks with low risk scores that may better match your comfort level.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681814213","isCrawlerRequest":true}